For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Tafamidis and Attruby represents a true change. These groundbreaking therapies protect the transthyretin protein, slowing its harmful build-up and reducing the impact of the illness. Patients are now experiencing benefits in their quality of